|Bioavailability||60% (when administered s.c.)|
|Elimination half-life||5–7 hours|
|Chemical and physical data|
|Molar mass||5916.89 g·mol−1|
|(what is this?)|
Insulin detemir, sold under the brand name Levemir among others, is a long-acting insulin used to treat both type 1 and type 2 diabetes. It is used by injection under the skin. It is effective for up to 24 hours.
Common side effects include low blood sugar, allergic reactions, pain at the site of injection, and weight gain. Use in pregnancy and breastfeeding appears safe. It works by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.
Insulin detemir was approved for medical use in the European Union in June 2004, and in the United States in June 2005. It is on the World Health Organization's List of Essential Medicines. In 2019, it was the 121st most commonly prescribed medication in the United States, with more than 5 million prescriptions.
It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.
Society and culture
On 13 June 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory for insulin determir after learning that 129,000 stolen vials reappeared and were being sold in the U.S. market. The FDA warned that the stolen vials "may not have been stored and handled properly and may be dangerous for patients to use." The stolen vials were identified as lots XZF0036, XZF0037, and XZF0038.
- "Levemir FlexPen 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- "Levemir InnoLet 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- "Levemir Penfill 100 units/ml solution for injection in cartridge - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- "Levemir- insulin detemir injection, solution". DailyMed. 24 March 2020. Retrieved 19 October 2020.
- "Levemir EPAR". European Medicines Agency (EMA). Retrieved 14 April 2020.
- "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Retrieved 14 April 2020.
- "Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". U.S. Food and Drug Administration (FDA). 26 July 2005. Retrieved 14 April 2020.
- World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.
- "Insulin Detemir - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.
- "FDA Issues Public Health Advisory Regarding Levemir Insulin". Food and Drug Administration. 13 June 2009. Archived from the original on 17 June 2009. Retrieved 9 March 2019.
- "Insulin detemir". Drug Information Portal. U.S. National Library of Medicine.